

CORRECTION

Correction: Determining Disease Intervention Strategies Using Spatially Resolved Simulations

Mark Read, Paul S. Andrews, Jon Timmis, Richard A. Williams, Richard B. Greaves, Huiming Sheng, Mark Coles, Vipin Kumar

The image for [Fig 4C](#) is incorrect. Please see the complete, corrected [Fig 4](#) here.



OPEN ACCESS

Citation: Read M, Andrews PS, Timmis J, Williams RA, Greaves RB, Sheng H, et al. (2015) Correction: Determining Disease Intervention Strategies Using Spatially Resolved Simulations. PLoS ONE 10(5): e0128170. doi:10.1371/journal.pone.0128170

Published: May 8, 2015

Copyright: © 2015 Read et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.




Fig 4. Effector T cell and clinical disease dynamics given anti-CD3 intervention at day 4. Various efficacies of anti-CD3 intervention have been administered at day 4, which corresponds with encephalitogenic T cell priming. (A) Median effector T cell peak population sizes. (B) CD4Th1 population sizes at 40 days post-induction of EAE; red and blue bars indicate large and non-large effect magnitude changes with respect to the control group, in black. (C) Proportion of simulations that reach a particular maximum clinical disease score. A-test effect magnitude levels are given: 1, 2 and 3 *'s represent small, medium and large effects respectively. (D & E) Proportion of simulations contracting particular clinical scores or greater over time, for control (D) and a drug efficacy of 80% (E).

doi:10.1371/journal.pone.0128170.g001

Reference

1. Read M, Andrews PS, Timmis J, Williams RA, Greaves RB, Sheng H, et al. (2013) Determining Disease Intervention Strategies Using Spatially Resolved Simulations. PLoS ONE 8(11): e80506. doi:10.1371/journal.pone.0080506 PMID: 24244694